

"Symmetry" in the Synthesis of the A-Ring of a Vitamin D Hybrid Analogue with Significant Transactivation Activity: A Combinatorial Sequence of Regioselective Propiolate-Ene, Catalytic Enantioselective Epoxidation and Carbonyl-Ene Cyclization Reactions[@]

Koichi Mikami,* Ayako Osawa, Akira Isaka, Eiji Sawa, Masaki Shimizu, Masahiro Terada,
Noboru Kubodera,[†] Kimie Nakagawa,[§] Naoko Tsugawa,[§] and Toshio Okano*[§]

Department of Chemical Technology, Tokyo Institute of Technology, Meguro-ku, Tokyo 152, Japan

[†]Chugai Pharmaceutical Co. Ltd., Chuo-ku, Tokyo 104, Japan


[§]Department of Hygienic Sciences, Kobe Pharmaceutical University, Higashinada-ku, Kobe 658, Japan

Received 8 December 1997; revised 24 January 1998; accepted 26 January 1998

Abstract: The combination of the regioselective propiolate-ene reaction, catalytic enantioselective epoxidation and catalytic enantioselective carbonyl-ene cyclization completes the synthesis of the A ring of the hybrid 19-nor-22-oxa D₃ analogue (1), which shows the significant activity in transactivation.

© 1998 Elsevier Science Ltd. All rights reserved.

Basic research on the synthesis of analogues of the biologically active form of vitamin D₃, 1 α ,25-dihydroxyvitamin D₃ [1 α ,25(OH)₂D₃], has brought about the development of an important new field in medicinal chemistry.¹ A number of analogues have been synthesized and used to clarify the mode of action of vitamin D hormones and find new therapeutically useful compounds. These analogues are useful not only for calcium metabolism disorder and bone diseases, but also for differentiation of myelocytic leukemias and the treatment of psoriasis.² 10-Oxo-19-nor-25(OH)D₃ has been reported to exhibit a selective activity for differentiation of myelocytic leukemias.³ 19-Nor-1 α ,25(OH)₂D₃ also shows a selective activity profile, *i.e.*, high potency in differentiation of malignant cells, but low calcemic liability.⁴ Furthermore, 22-oxa-1 α ,25(OH)₂D₃ shows a significant activity in the inhibition of cancer cell growth.⁵ Therefore, we might design the hybridization analogue 19-nor-22-oxa-1 α ,25(OH)₂D₃ (1).




Scheme 1

Reported herein is a "symmetry"-based enantiospecific synthesis of the A-ring. This is accomplished by a sequence of regioselective⁶ propiolate-ene reaction⁷ of a homoallylic alcohol followed by catalytic enantioselective Katsuki-Sharpless epoxidation⁸ of the resultant allylic alcohol and then catalytic enantioselective carbonyl-ene cyclization^{9a} (Scheme 1). The hybrid analogue (**1**) thus synthesized is found to possess a greater ability than $1\alpha,25(\text{OH})_2\text{D}_3$ to transactivate a rat 25-hydroxyvitamin D₃ 24-hydroxylase gene despite an extremely low binding affinity for the nuclear calf-thymus vitamin D receptor, VDR.


It occurred to us that the intramolecular 6-(2,4)^{9a} carbonyl-ene cyclization of (*R*)-MPMoxy¹⁰ (benzyloxyethyl)hexenal (**2**) catalyzed by a (*R*)-binaphthol-derived titanium (BINOL-Ti) complex would provide the desired cyclohexanediol with high enantiomeric purity (Scheme 1). Because the pseudo C₂-symmetry¹¹ of the (*E*)- and (*Z*)-isomers of the ene cyclization product (**3**) could afford the same single compound **4** after deprotection. As expected, the carbonyl-ene cyclization of **2** by the (*R*)-BINOL-Ti catalyst¹² (5 mol%) took place at room temperature¹³ to give the ene cyclization product (**3**) with extremely *R,R* stereochemistry, though as a geometrical mixture [(*trans, Z*), (*trans, E*), (*cis, ZE*) = 75 : 23 : 2 as determined by GLC (OV-1701, 270 °C) analysis], in 65% isolated yield. Both geometrical isomers (*E*)- and (*Z*)-**3** can be transformed to the identical DeLuca intermediate (**5**)^{4,14} after deprotection of MPM ether. In contrast, the enantiomeric form of (*S*)-BINOL-Ti catalyst gave four possible isomers (*trans, Z*), (*trans, E*), (*cis, Z*), and (*cis, E*) in a ratio of 32 : 8 : 32 : 28.

The Lewis acid-catalyzed carbonyl-ene cyclization would proceed via 6-membered transition states¹⁵ to provide the (*trans, Z*)- and (*trans, E*)-**3** depending on the balance of acyclic allylic 1,2-strain¹⁶ (*T_Z*) and repulsion between the sterically demanding BINOL-Ti catalyst and benzyloxymethyl group (*T_E*).¹⁷ Further transformation of the (*trans, Z*)- and (*trans, E*)-**3** to the Wittig reagent (**6**)⁴ for olefination of 22-oxa-C,D ring (**7**) lead to the hybrid analogue of 19-nor-22-oxa- $1\alpha,25(\text{OH})_2\text{D}_3$ (**1**) (Scheme 2).



Scheme 2

$1\alpha,25(\text{OH})_2\text{D}_3$ mediates its biological activities through specific binding to VDR which forms a hetero conjugate with a nuclear accessory factor (NAF) *i.e.*, retinoid X receptor (RXR) and subsequently the hetero conjugate binds to the vitamin D responsive element (VDRE) to induce gene transcriptions. Therefore, a high binding affinity for VDR has been considered necessary for analogues to possess high biological activity. However, we have found a counter example to this principle that our hybrid analogue (**1**) thus synthesized has a greater ability to transactivate a rat 25-hydroxyvitamin D₃ 24-hydroxylase gene (twice as active as $1\alpha,25(\text{OH})_2\text{D}_3$) in spite of a 33-fold reduction in binding affinity for VDR.



a) EtAlCl_2 , CH_2Cl_2 , rt; b) DIBAL-H, toluene, -78°C ; c) $(-)\text{-DET}$ / $\text{Ti}(\text{OPr})_4$ (30 mol% each), TBHP, MS 4A, CH_2Cl_2 , -20°C ; d) Red-Al, MeOH , THF, rt; e) *p*-anisaldehyde dimethylacetal, PPTS, CH_2Cl_2 , rt; f) DIBAL-H, CH_2Cl_2 , 0°C to rt; g) PCC, MS 3A, CH_2Cl_2 , rt

Scheme 3

The preparation of the ene-cyclization substrate ((*R*)-2) is worth mentioning. The ene substrate 2 was prepared in 94% ee via catalytic enantioselective epoxidation⁸ of allylic alcohol (8) which was in turn obtained through regioselective propiolate-ene reaction of homoallylic ethers with methyl propiolate using EtAlCl_2 ^{6a} as the promoter (Scheme 3). Thus, the combination of the regioselective propiolate-ene reaction, catalytic enantioselective epoxidation and catalytic enantioselective carbonyl-ene cyclization completes the synthesis of the A ring of the hybrid 19-nor-22-oxa D₃ analogue (1). Furthermore, the present synthesis exploits the latent C₂-symmetry in the A-ring of 1, which shows the significant activity in transactivation.

Acknowledgments: We are grateful to Emeritus Professor Nobuo Ikekawa of Tokyo Institute of Technology for his encouragement and useful discussion.

REFERENCES AND NOTES

- @ A part of this vitamin D synthesis has been reported in the 67th Ann. Meeting of Chem. Soc. Jpn. March (1994): Abst. No. 2C107.
- Reviews on the synthesis and structure-function relationships of vitamin D analogues: Bouillon, R.; Okamura, W. H.; Norman, A. W. *Endocrine Reviews* **1995**, *16*, 200-257. Zhu, G.-D.; Okamura, W. H. *Chem. Rev.* **1995**, *95*, 1877-1952. Dai, H.; Posner, G. H. *Synthesis* **1994**, 1383-1398. Special issue: Uskokovic, M. ed. *BioMed. Chem. Lett.* **1993**, *3*, No. 9.
- Ettinger, R. A.; DeLuca, H. F. *Adv. Drug Res.* **1996**, *28*, 269-312. "Vitamin D: A Chemical, Biochemical, and Clinical Update"; Norman, A. W.; Schaefer, K.; Grigoleit, H. G.; Herrath, D., Ed.; Walter de Gruyter: Berlin, 1985.
- Gray, T. K.; Millington, D. S.; Maltby, D. A.; Williams, M. E.; Cohen, M. S.; Dodd, R. C., *Proc. Natl. Acad. Sci. USA*, **1985**, *82*, 8218-8221.
- Perlman, K. L.; Siciniski, R. R.; Schnoes, H. K.; DeLuca, H. F., *Tetrahedron Lett.* **1990**, *31*, 1823-1824. Perlman, K. L.; Swenson, R. E.; Paaren, H. E.; Schnoes, H. K.; DeLuca, H. F.; *Tetrahedron Lett.*, **1991**, *32*, 7663-7666. Perlman, K. L.; DeLuca, H. F. *Tetrahedron Lett.*, **1992**, *33*, 2937-2940.
- Murayama, E.; Miyamoto, K.; Kubodera, N.; Mori, T.; Matsunaga, I. *Chem. Pharm. Bull.* **1986**, *34*, 4410-4413. Kubodera, N.; Watanabe, H.; Kawanishi, T.; Matsumoto, M., *Chem. Pharm. Bull.* **1992**, *40*, 1494-1499.

6. (a) Shimizu, M. Ph. D. dissertation, Tokyo Institute of Technology, Dec. 1993. (b) Regioselective carbonyl-ene reactions with allylic and homoallylic alcohols: Mikami, K.; Shimizu, M.; Nakai, T. *J. Org. Chem.* **1991**, *56*, 2952-2953.
7. Snider, B. B. *Acc. Chem. Res.* **1980**, *13*, 426-432.
8. Reviews: Katsuki, T.; Martin, V. S. *Org. React.* **1996**, *48*, 1-299. Johnson, R. A.; Sharpless, K. B. in "Comprehensive Organic Synthesis"; Trost, B. M.; Fleming, I., Eds.; Pergamon: London, 1991; Vol 7, pp. 389-436. For the A-ring synthesis in 1 α ,25(OH) $_2$ D $_3$, see: Nagasawa, K.; Zako, Y.; Ishihara, H.; Shimizu, I. *Tetrahedron Lett.* **1991**, *32*, 4937-4940. Kabat, M. M.; Lange, M.; Wovkulich, P. M.; Uskokovic, M. R. *Tetrahedron Lett.* **1992**, *33*, 7701-7704. Nagasawa, K.; Ishihara, H.; Zako, Y.; Shimizu, I. *J. Org. Chem.* **1993**, *58*, 2523-2529.
9. Reviews: (a) Mikami, K.; Shimizu, M. *Chem. Rev.* **1992**, *92*, 1021-1050. (b) Snider, B. B. in "Comprehensive Organic Synthesis"; Trost, B. M.; Fleming, I., Eds.; Pergamon: London, 1991; Vol. 2, pp. 527-561 and Vol. 5, pp. 1-27. (c) Oppolzer, W.; Snieckus, V. *Angew. Chem., Int. Ed. Engl.* **1978**, *17*, 476-486. (d) Hoffmann, H. M. R. *Angew. Chem., Int. Ed. Engl.* **1969**, *8*, 556-577.
10. MPM: *p*-methoxyphenylmethyl.
11. Symmetry in syntheses: Reviews: Ward, R. S.; *Chem. Soc. Rev.* **1990**, *19*, 1-19; Nagao, Y.; Fujita, E. *J. Synth. Org. Chem., Jpn.* **1984**, *42*, 622-634; Schreiber, S. L. *Chem. Scripta* **1987**, *27*, 563-566; Baba, S. E.; Sator, K.; Poulin, J.-C.; Kagan, H. B. *Bull. Soc. Chim. Fr.* **1994**, *131*, 525-533. (a) Ward, D. E.; How, D.; Liu, Y. *J. Am. Chem. Soc.* **1997**, *119*, 1884-1894. (b) Hoye, T. R.; Peck, D. R.; Swanson, T. A. *J. Am. Chem. Soc.* **1984**, *106*, 2738-2739. (c) Mislow, K.; Siegel, J. *J. Am. Chem. Soc.* **1984**, *106*, 3319-3328. (d) Hatakeyama, S.; Sakurai, K.; Takano, S. *J. Chem. Soc., Chem. Commun.* **1985**, 1759-1761. (e) Jager, V.; Schroter, D.; Hafele, B. *Angew. Chem., Int. Ed. Engl.* **1986**, *25*, 87-89. (f) Schreiber, S. L.; Schreiber, T. S.; Smith, D. B. *J. Am. Chem. Soc.* **1987**, *109*, 1525-1529. (g) Kobayashi, Y.; Kato, N.; Shimazaki, I.; Sato, F. *Tetrahedron Lett.* **1988**, *29*, 6297-6300. (h) Partridge, J. J.; Chadha, N. K.; Uskokovic, M. R. *J. Am. Chem. Soc.* **1973**, *95*, 532-540 and 7171-7172.
12. (a) Mikami, K.; Terada, M.; Nakai, T. *J. Am. Chem. Soc.* **1990**, *112*, 3949-3954. (b) Mikami, K.; Terada, M.; Nakai, T. *J. Am. Chem. Soc.* **1989**, *111*, 1940-1941. (c) Mikami, K.; Terada, M.; Narisawa, S.; Nakai, T. *Org. Synth.* **1993**, *71*, 14-21.
13. For asymmetric (2,4) and (3,4) ene cyclizations catalyzed by binaphthol-derived titanium complex, see: Mikami, K.; Sawa, E.; Terada, M. *Tetrahedron Asym.* **1991**, *2*, 1403-1412.
14. ^1H NMR (300 MHz, CDCl_3) δ 0.037 (bs, 3H), 0.044 (bs, 3H), 0.052 (bs, 6H), 0.87 (s, 18H), 1.38 (br, 1H), 1.63 (ddd, J = 13.0, 8.7, 3.3 Hz, 1H), 1.73-1.85 (m, 1H), 2.05 (dd, J = 13.0, 8.7 Hz, 1H), 2.18 (dd, J = 13.0, 3.3 Hz, 1H), 2.29-2.37 (m, 2H), 3.96-4.07 (m, 2H), 4.10-4.15 (m, 2H), 5.59 (t, J = 7.2 Hz, 1H); $[\alpha]_D^{29}$ +15.0 (c 0.325, CHCl_3).
15. Mikami, K.; Loh, T.-P.; Nakai, T. *Tetrahedron Lett.* **1988**, *29*, 6305-6308. For STO-3G and 3-21G calculations on 5-membered transition states (ref. 9d) of thermal ene reactions, see: Loncharich, R. J.; Houk, K. N. *J. Am. Chem. Soc.* **1987**, *109*, 6947-6952. For axial vs. equatorial orientation of carbonyl group in ene cyclization reactions, see: Maruoka, K.; Ooi, T.; Yamamoto, H. *J. Am. Chem. Soc.* **1990**, *112*, 9011-9012; Ooi, T.; Maruoka, K.; Yamamoto, H. *Tetrahedron* **1994**, *50*, 6505-6522. However, they proposed an equatorial arrangement of carbonyl group complexed with sterically bulky MABR leading to 1,3-*cis*-cyclohexanol. Also see: Marshall, J. A.; Anderson, M. W. *J. Org. Chem.* **1992**, *57*, 5851-5856. For the formation of 1,3-*trans*-cyclohexanols by using Me_2AlCl , see: Johnston, M. I.; Kwass, J. A.; Beal, R. B.; Snider, B. B. *J. Org. Chem.* **1987**, *52*, 5419-5424.
16. Reviews: Hoffmann, R. W. *Chem. Rev.* **1989**, *89*, 1841-1860. Mikami, K.; Shimizu, M. In "Advances in Detailed Reaction Mechanisms" Coxon, J. Ed.; JAI Press: London, 1994; Vol. 3, pp. 45-77. For cyclic allylic strain concept, see: Johnson, F. *Chem. Rev.* **1968**, *68*, 375-413.
17. Sterically bulky *tert*-butyldiphenylsilyl protective group instead of benzyl group leads to the four possible isomers (*trans*, *Z*), (*trans*, *E*), (*cis*, *Z*), and (*cis*, *E*) in a ratio of 48 : 40 : 8 : 4.